DA
TXG icon

Duality Advisers’s 10x Genomics TXG Stock Holding History

Duality Advisers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,983
Closed -$1.28M – 719
2023
Q2 		$1.28M Buy
+22,983
New +$1.24M 0.16% 237
2021
Q4 		– Sell
-18,566
Closed -$2.7M – 686
2021
Q3 		$2.7M Buy
+18,566
New +$3.19M 0.21% 199

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Duality Advisers's TXG Position: Q3 2023 in Review

Duality Advisers sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 22,983 shares — an estimated $1.28M sold.

Duality Advisers first reported a position in TXG in Q3 2021 and held it in 2 quarters. The position peaked at $2.7M in Q3 2021. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

  • Duality Advisers reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
  • Duality Advisers sold 22,983 10x Genomics shares in Q3 2023, an estimated $1.28M.
  • Duality Advisers first reported a position in 10x Genomics in Q3 2021 and held it in 2 quarters.
  • Duality Advisers's 10x Genomics position peaked at $2.7M in Q3 2021.
  • 256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Duality Advisers's 13F filing for Q3 2023, filed 2 Nov 2023.